Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | NAE1 | Q13564 | 8/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 8/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SAE1 | Q9UBE0 | 7/20 | 0.34 |
| ▸ | UBA2 | Q9UBT2 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22401404 | 0.88 | ACP1 (0.39) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456067 | 0.88 | ACP1 (0.39) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456033 | 0.85 | NAE1 (0.40) | TYMPNAE1UBA3SAE1UBA2 | |
| SCHEMBL23455991 | 0.82 | TYMP (0.37) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456027 | 0.81 | TYMP (0.36) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456175 | 0.80 | TYMP (0.37) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456061 | 0.80 | TYMP (0.36) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456070 | 0.78 | NAE1 (0.34) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23455989 | 0.77 | NAE1 (0.40) | TYMPSLC6A1SLC6A11NAE1UBA3 | |
| SCHEMBL23456278 | 0.74 | NAE1 (0.41) | TYMPSLC6A1SLC6A11NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | TYMP 1316/4885SLC6A1 3437/4885SLC6A11 3399/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | TYMP 1316/4885SLC6A1 3437/4885SLC6A11 3399/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | TYMP 1316/4885SLC6A1 3437/4885SLC6A11 3399/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | TYMP 1316/4885SLC6A1 3437/4885SLC6A11 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.